GlaxoSmithKline PLC Update
Join myFT Daily Digest to be the first to know about GlaxoSmithKline PLC news.
A third Covid-19 shot using GlaxoSmithKline’s additional technology has started a late stage in a clinical trial, while the British drugmaker wants to get lost in the development of a coronavirus vaccine.
The vaccine, manufactured by South Korean SK Bioscience, will be tested in 4,000 people, after previous studies showed that all participants developed strong neutralizing antibody responses.
The companies hope to distribute doses through the Covax facility, which provides low- and middle-income countries with vaccines in the first half of next year, if the results are positive.
Thomas Breuer, chief medical officer of GSK Vaccines, said the company was happy to contribute to the effort and work with SK Bioscience to deliver the vaccine on a scale if approved.
“Although many countries have made good progress with vaccination, there is still a need for affordable and affordable Covid-19 vaccines to ensure equitable access and to protect people around the world,” he said.
The British pharmaceutical company decided to supply the additive rather than create its own vaccine from scratch in the hope of having more chances of success.
But despite being one of the largest vaccine makers in the world, it lagged behind in the race for a Covid-19 jab. Competitors Pfizer, BioNTech and Moderna will generate tens of billions in revenue from their vaccines this year.
His partnership with French drugmaker Sanofi suffered after a dosing error meant the couple had to repeat an early stage. The Phase 3 trial for the vaccine – and another with Canadian biotechnology company Medicago – will report results in the fourth quarter.
GSK is also works with CureVac to create a second generation Covid-19 vaccine using mRNA, the technology that was successful for BioNTech / Pfizer and Moderna. The shot is aimed at aimed at various variants of the Sars-Cov-2 virus simultaneously.
GSK CEO Emma Walmsley was under pressure to fill the company’s medicine pipeline after activist investor Elliott Management took a stake of more than a billion pounds to bring about change. She will further invest in it broader vaccine business, including possible shots for the widespread respiratory disease RSV that is in late-stage tests.
Interim data from the SK Bioscience vaccine showed that the participants’ antibodies were five to eight times higher than patients recovering from Covid-19. No security issues were identified.
During Phase 3 trials, the safety and efficacy of the SK Bioscience GBP510 vaccine are measured on the Oxford / AstraZeneca jab. Now that approved vaccines are available, placebos no longer use comparisons in trials.
Jae-yong Ahn, CEO of SK Bioscience, said he was’ grateful that we were able to progress to the Phase 3 study with the unprecedented support of global initiatives, including GSK, Coalition for Epidemic Preparedness Initiative and the Bill & Melinda Gates Foundation ‘.